Stuart Tross - MannKind Corp Chief People Officer

MNKD Stock  USD 4.10  0.05  1.23%   

Executive

Dr. Stuart A. Tross, Ph.D., serves as Chief People Officer of the Company. Dr. Tross will be integral in accelerating the company development into a worldclass, global biopharmaceutical company centered on the value of its human capital since 2017.
Age 57
Tenure 7 years
Address 1 Casper Street, Danbury, CT, United States, 06810
Phone818 661 5000
Webhttps://www.mannkindcorp.com
Tross joins MannKind with several decades of leadership experience in the life sciences industry. From 2006 to 2016 he served in roles of increasing responsibility at Amgen, the last three years as Senior Vice President and Chief Human Resources Officer responsible for Human Resources and Security on a global basis. From 1998 to 2006 he served in a series of leadership roles at BristolMyers Squibb, the last three years as Vice President and Global Head of Human Resources for Mead Johnson Company. Stuart received a B.S. degree from Cornell University and M.S. and Ph.D. degrees in IndustrialOrganization Psychology from the Georgia Institute of Technology.

Stuart Tross Latest Insider Activity

Tracking and analyzing the buying and selling activities of Stuart Tross against MannKind Corp stock is an integral part of due diligence when investing in MannKind Corp. Stuart Tross insider activity provides valuable insight into whether MannKind Corp is net buyers or sellers over its current business cycle. Note, MannKind Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell MannKind Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

MannKind Corp Management Efficiency

The company has return on total asset (ROA) of 0.0172 % which means that it generated a profit of $0.0172 on every $100 spent on assets. This is way below average. MannKind Corp's management efficiency ratios could be used to measure how well MannKind Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of April 18, 2024, Return On Tangible Assets is expected to decline to -0.03. In addition to that, Return On Capital Employed is expected to decline to 0.03. At present, MannKind Corp's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 392.1 M, whereas Non Current Assets Total are forecasted to decline to about 87.1 M.
The company currently holds 382.38 M in liabilities with Debt to Equity (D/E) ratio of 9.93, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MannKind Corp has a current ratio of 3.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist MannKind Corp until it has trouble settling it off, either with new capital or with free cash flow. So, MannKind Corp's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MannKind Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MannKind to invest in growth at high rates of return. When we think about MannKind Corp's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

John BatsonHome Federal Bancorp
N/A
Janine JakubauskasProvident Bancorp
N/A
DeNell MitchellHome Federal Bancorp
68
Mauricio AlvarezBetterware De Mexico
54
Kenneth FisherProvident Bancorp
N/A
Anne LapointeProvident Bancorp
N/A
Alejandro MirandaBetterware De Mexico
N/A
Kimberly ScholtzProvident Bancorp
N/A
Joseph KenneyProvident Bancorp
N/A
Reynaldo VizcarraMendezBetterware De Mexico
58
Pilar SanchezBetterware De Mexico
N/A
Dawn FitzgeraldWilliamsHome Federal Bancorp
N/A
Juan HernandezBetterware De Mexico
N/A
Kevin BartonProvident Bancorp
N/A
Carlos DoormannBetterware De Mexico
53
Donna LewisHome Federal Bancorp
61
Jean KimProvident Bancorp
50
Denise GallantProvident Bancorp
N/A
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California. Mannkind Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 348 people. MannKind Corp (MNKD) is traded on NASDAQ Exchange in USA. It is located in 1 Casper Street, Danbury, CT, United States, 06810 and employs 411 people. MannKind Corp is listed under Biotechnology category by Fama And French industry classification.

Management Performance

MannKind Corp Leadership Team

Elected by the shareholders, the MannKind Corp's board of directors comprises two types of representatives: MannKind Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MannKind. The board's role is to monitor MannKind Corp's management team and ensure that shareholders' interests are well served. MannKind Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MannKind Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Bedard, Senior Affairs
Michael Friedman, Independent Director
Lauren Sabella, Executive COO
McCauley JD, Chief Officer
Raymond Urbanski, Corporate Vice President Chief Medical Officer
David Thomson, Corporate Vice President General Counsel, Corporate Secretary
Linda Adreveno, Senior Vice President - Human Resources
MS MBA, Chief Officer
Matthew PharmD, Senior Unit
Ronald Consiglio, Independent Director
Michael Castagna, Chief Commercial Officer
Joseph Kocinsky, CTO and Sr. VP of Technical Operations
Sanjay MBA, Executive Operations
Steven Binder, CFO, Principal Accounting Officer
Thomas MD, Chief Officer
Dr JD, General VP
David MacCallum, Independent Director
Burkhard MD, Executive Officer
Stuart Tross, Chief People Officer
Kent Kresa, Lead Independent Director
Alfred Mann, Founder and Executive Chairman
Rose Alinaya, Chief Accounting Officer
Juergen Martens, COO
Christine Mundkur, Director
Michael PharmD, CEO Director
Henry Nordhoff, Independent Director
Rosabel Alinaya, Acting CFO, Senior Vice President Chief Accounting Officer
Diane Palumbo, Corporate Vice President - Human Resources
Patrick McCauley, Chief Commercial Officer
James Shannon, Director
Matthew Pfeffer, Corporate Vice President and CFO

MannKind Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MannKind Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether MannKind Corp is a strong investment it is important to analyze MannKind Corp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MannKind Corp's future performance. For an informed investment choice regarding MannKind Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MannKind Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry.
For information on how to trade MannKind Stock refer to our How to Trade MannKind Stock guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for MannKind Stock analysis

When running MannKind Corp's price analysis, check to measure MannKind Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MannKind Corp is operating at the current time. Most of MannKind Corp's value examination focuses on studying past and present price action to predict the probability of MannKind Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MannKind Corp's price. Additionally, you may evaluate how the addition of MannKind Corp to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Global Correlations
Find global opportunities by holding instruments from different markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Is MannKind Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MannKind Corp. If investors know MannKind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MannKind Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.04)
Revenue Per Share
0.745
Quarterly Revenue Growth
0.622
Return On Assets
0.0172
The market value of MannKind Corp is measured differently than its book value, which is the value of MannKind that is recorded on the company's balance sheet. Investors also form their own opinion of MannKind Corp's value that differs from its market value or its book value, called intrinsic value, which is MannKind Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MannKind Corp's market value can be influenced by many factors that don't directly affect MannKind Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MannKind Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if MannKind Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MannKind Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.